RASIRC, the steam purification company, will present poster #76, Trace Metal Removal Efficiency of a RainMaker Humidifier at the 31st Annual Fuel Cell Seminar & Exposition being held in San Antonio, TX, October 15-19, 2007.
IBM and its joint development partners -- AMD, Chartered Semiconductor Manufacturing Ltd., Freescale, Infineon, and Samsung -- today announced an innovative approach to speed the implementation of a breakthrough material known as 'high-k/metal gate' in next generation 32 nanometer (32nm) computer chips.
Raymor Industries Inc. is pleased to announce that further to its annual general meeting held on the 19th of September, 2007, the shareholders approved the election of six new individuals to its board of directors until the next annual general meeting.
API Nanotronics Corp. is pleased to announce that its Chief Technology Officer, Dr. Martin Moskovits, was recently invited to chair the discussion session on "New Frontiers of Science and Technology, Nanotechnology," in Kyoto, Japan on October 7th - 9th.
BIOTECHNICA - the flagship trade fair for the European biotech industry - continues to consolidate its position as a leader, and the outstanding quality of exhibitors and trade visitors at this year's event surpassed all expectations.
Advanced Nanotechnology Ltd reports sales to customers for the September 2007 quarter were $960,000, up 102pc from $474,000 in the June 2007 quarter and up 188pc from $333,000 in the September 2006 quarter.
The Nano-Network and NanoBusiness Alliance, today announced corporate event sponsors and additional keynote speakers for the 2007 Nano App Summit, to be held October 22-25, 2007, at the Ritz Carlton Hotel in Cleveland, Ohio.
BIND Biosciences, Inc., a privately held biopharmaceutical company developing therapeutic targeted nanoparticles, announced today that it has received a three year $2,000,000 award from the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP) to further develop its platform for high-throughput formulation and selection of targeted nanoparticles.
Nanotherapeutics, Inc., today announced that it has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases to develop an inhaled version of the injectable drug, gentamicin, a broad-spectrum antibiotic that is used as a first-line therapy for pneumonic plague and tularemia, Category A bioterrorism agents.
Non-profit NanoBioNexus (NBN) - already widely acclaimed for its educational forums and nanobiotechnology expertise in the United States, has moved into the international leadership circles for innovative technologies with its International Alliance Initiative.